Company news

AtaiBeckley Inc. news in 2024

AtaiBeckley Inc.'s news releases, calls and decks from 2024, newest first.

View company

atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

November 12, 2024

atai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit

October 14, 2024

atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

September 3, 2024

atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

August 12, 2024

atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT)

August 12, 2024

atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference

August 6, 2024

atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference

June 25, 2024

atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a

June 19, 2024

atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference

May 30, 2024

atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors

May 22, 2024

atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates

May 14, 2024

atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression

April 23, 2024

atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology

April 16, 2024

atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights

March 27, 2024

atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression

March 26, 2024

atai Life Sciences advances VLS-01 for treatment-resistant depression

March 11, 2024

atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01

March 3, 2024

atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference

February 27, 2024

atai Life Sciences Appoints Anne Johnson as Chief Financial Officer

February 5, 2024

atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics

January 3, 2024

atai Life Sciences Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01 (R-MDMA)

January 1, 2024

Decks in 2024